Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 26.72
NAS:LIFE's Cash to Debt is ranked lower than
52% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: 46.43 vs. NAS:LIFE: 26.72 )
Ranked among companies with meaningful Cash to Debt only.
NAS:LIFE' s Cash to Debt Range Over the Past 10 Years
Min: 1.54  Med: 21.98 Max: N/A
Current: 26.72
Interest Coverage No Debt
NAS:LIFE's Interest Coverage is ranked higher than
53% of the 458 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NAS:LIFE: No Debt )
Ranked among companies with meaningful Interest Coverage only.
NAS:LIFE' s Interest Coverage Range Over the Past 10 Years
Min: 0  Med: 0 Max: No Debt
Current: No Debt
Z-Score: -1.19
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
ROE (%) -61.15
NAS:LIFE's ROE (%) is ranked lower than
67% of the 878 Companies
in the Global Biotechnology industry.

( Industry Median: -33.45 vs. NAS:LIFE: -61.15 )
Ranked among companies with meaningful ROE (%) only.
NAS:LIFE' s ROE (%) Range Over the Past 10 Years
Min: -399.23  Med: -399.23 Max: -61.15
Current: -61.15
-399.23
-61.15
ROA (%) -53.95
NAS:LIFE's ROA (%) is ranked lower than
69% of the 971 Companies
in the Global Biotechnology industry.

( Industry Median: -29.51 vs. NAS:LIFE: -53.95 )
Ranked among companies with meaningful ROA (%) only.
NAS:LIFE' s ROA (%) Range Over the Past 10 Years
Min: -80.59  Med: -63.83 Max: -50.3
Current: -53.95
-80.59
-50.3
ROC (Joel Greenblatt) (%) -3500.51
NAS:LIFE's ROC (Joel Greenblatt) (%) is ranked lower than
77% of the 931 Companies
in the Global Biotechnology industry.

( Industry Median: -372.06 vs. NAS:LIFE: -3500.51 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NAS:LIFE' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -3500.51  Med: -1063.39 Max: -780.12
Current: -3500.51
-3500.51
-780.12
» NAS:LIFE's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

LIFE Guru Trades in Q4 2015

RS Investment Management 1,206,249 sh (+11.46%)
» More
Q1 2016

LIFE Guru Trades in Q1 2016

RS Investment Management 1,579,892 sh (+30.98%)
» More
Q2 2016

LIFE Guru Trades in Q2 2016

RS Investment Management Sold Out
» More
Q3 2016

LIFE Guru Trades in Q3 2016

Jim Simons 69,200 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with LIFE

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:NAS:ANTH, NAS:PPHM, NAS:ALDX, OTCPK:NURPF, NAS:AFMD, NAS:NEPT, OTCPK:CNBX, NAS:ADMA, OTCPK:CWBR, AMEX:CRMD, NAS:CATB, NAS:TCON, NAS:CALA, NAS:BUR, OTCPK:RCAR, NAS:ORMP, OTCPK:THCBF, NAS:AGLE, NAS:DRNA, NAS:CAPR » details
Traded in other countries:471.Germany,
aTyr Pharma Inc is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its knowledge of Physiocrine biology, a newly discovered set of physiological modulators.

aTyr Pharma Inc was incorporated in the state of Delaware on September 8, 2005. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its knowledge of Physiocrine biology, a newly discovered set of physiological modulators. It has discovered approximately 300 Physiocrines, a class of naturally occurring human proteins that it promotes homeostasis, a fundamental process of restoring stressed or diseased tissue to a healthier state. The Company is currently conducting a multi-national exploratory Phase 1b/2 clinical trial of Resolaris in adult patients with FSHD in the European Union. This randomized, double-blind, placebo-controlled trial is designed to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of multiple intravenous doses of Resolaris in adults with FSHD. Its initial therapeutic efforts target severe, rare disease indications in which patients suffer from the immune-related consequences of their genetic disease. It contracts with third parties for the manufacturing and testing of its product candidates for preclinical studies and clinical trials. It does not own or operate manufacturing facilities for the production of clinical quantities of its product candidates. Government authorities in the United States, including federal, state, and local authorities, and in other countries, extensively regulate, among other things, the manufacturing, research and clinical development, marketing, labeling and packaging, storage, distribution, post-approval monitoring and reporting, advertising and promotion, pricing, and export and import of pharmaceutical and biological products, such as those it is developing.

Ratios

vs
industry
vs
history
P/B 1.14
LIFE's P/B is ranked higher than
91% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: 3.50 vs. LIFE: 1.14 )
Ranked among companies with meaningful P/B only.
LIFE' s P/B Range Over the Past 10 Years
Min: 0  Med: 0 Max: 42.54
Current: 1.14
0
42.54
Current Ratio 6.17
LIFE's Current Ratio is ranked higher than
62% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. LIFE: 6.17 )
Ranked among companies with meaningful Current Ratio only.
LIFE' s Current Ratio Range Over the Past 10 Years
Min: 1.63  Med: 6.41 Max: 12.69
Current: 6.17
1.63
12.69
Quick Ratio 6.17
LIFE's Quick Ratio is ranked higher than
63% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.94 vs. LIFE: 6.17 )
Ranked among companies with meaningful Quick Ratio only.
LIFE' s Quick Ratio Range Over the Past 10 Years
Min: 1.63  Med: 6.41 Max: 12.69
Current: 6.17
1.63
12.69

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price/Net Cash 1.46
LIFE's Price/Net Cash is ranked higher than
94% of the 518 Companies
in the Global Biotechnology industry.

( Industry Median: 6.05 vs. LIFE: 1.46 )
Ranked among companies with meaningful Price/Net Cash only.
LIFE' s Price/Net Cash Range Over the Past 10 Years
Min: 0.94  Med: 1.91 Max: 4.9
Current: 1.46
0.94
4.9
Price/Net Current Asset Value 1.38
LIFE's Price/Net Current Asset Value is ranked higher than
94% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 5.53 vs. LIFE: 1.38 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
LIFE' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.92  Med: 1.87 Max: 4.74
Current: 1.38
0.92
4.74
Price/Tangible Book 1.15
LIFE's Price/Tangible Book is ranked higher than
93% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. LIFE: 1.15 )
Ranked among companies with meaningful Price/Tangible Book only.
LIFE' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.76  Med: 1.45 Max: 3.14
Current: 1.15
0.76
3.14
Earnings Yield (Greenblatt) (%) -248.77
LIFE's Earnings Yield (Greenblatt) (%) is ranked lower than
100% of the 942 Companies
in the Global Biotechnology industry.

( Industry Median: -8.50 vs. LIFE: -248.77 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
LIFE' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -78358.53  Med: 0 Max: 728365.11
Current: -248.77
-78358.53
728365.11

More Statistics

EPS (TTM) $ -2.56
Short Percentage of Float5.37%
52-Week Range $2.48 - 10.93
Shares Outstanding (Mil)23.72
» More Articles for LIFE

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
aTyr Pharma to Present at the BMO Prescriptions for Success Healthcare Conference Dec 09 2016
aTyr Pharma, Inc. :LIFE-US: Earnings Analysis: Q3, 2016 By the Numbers : December 5, 2016 Dec 05 2016
ATYR PHARMA INC Financials Nov 23 2016
aTyr Pharma Enters into $20 Million Credit Facility Nov 21 2016
ATYR PHARMA INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a... Nov 21 2016
aTyr Pharma Enters into $20 Million Credit Facility Nov 21 2016
aTyr Pharma (LIFE) Looks Good: Stock Adds 5.9% in Session Nov 18 2016
Atyr Pharma reports 3Q loss Nov 14 2016
Atyr Pharma reports 3Q loss Nov 14 2016
aTyr Pharma Announces Third Quarter 2016 Operating Results Nov 14 2016
ATYR PHARMA INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Nov 14 2016
aTyr Pharma Announces Third Quarter 2016 Operating Results Nov 14 2016
ATYR PHARMA INC Files SEC form 8-K, Regulation FD Disclosure Nov 07 2016
aTyr Pharma Receives Fast Track Designation (LIFE) Oct 26 2016
aTyr Receives FDA Fast Track Designation Oct 24 2016
aTyr Pharma Receives FDA Fast Track Designation for Resolaris™ to Treat Facioscapulohumeral... Oct 24 2016
aTyr Pharma Receives FDA Fast Track Designation for Resolaris™ to Treat Facioscapulohumeral... Oct 24 2016
Genovis signs license agreement with Life Technologies Corporation Oct 17 2016
BMO Sets $8 Target for Atyr Pharma (LIFE) Oct 10 2016
ATYR PHARMA INC Files SEC form 8-K, Regulation FD Disclosure, Other Events Oct 06 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)